The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Improvement in DLQI total score up to 32 weeks1,a,b

Created with Highcharts 8.0.4PlaceboCrossover to OTEZLA 30 mg BIDOTEZLA 30 mg
Week 16b
(n = 500)
(n = 247)
Week 32
(n = 422)
(n = 216)
Mean Change From BL in DLQI Score
(decrease indicates improvement)
Woman and man pointing

aESTEEM 1 study. Full analysis set, LOCF. Includes patients with baseline DLQI total score >5.

bP < 0.001.

OTEZLA achieves significant and sustained improvement in QoL1

BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; DLQI, Dermatology Life Quality Index; LOCF, last observation carried forward; QoL, quality of life.


Significant and sustained improvement in quality of life2,a

PSOchartstables01381a 1
Woman feeding ducks

aLIBERATE study. Week 16 and week 104 responses were determined using the LOCF methodology. The analysis for week 16 includes all patients in the ITT group, while the week 104 analysis includes patients who entered the OTEZLA extension phase and were treated in the phase.

bP = 0.0032, OTEZLA vs placebo.

  • At week 16, significantly more patients achieved a minimal clinically important difference (MCID)* in DLQI score (5-point change from baseline in those patients with DLQI >5 at baseline) with OTEZLA vs placebo2

In biologic-naïve patients, OTEZLA achieves significant
and sustained improvement in QoL for up to 2 years2,3

*Response defined as a decrease of ≥5 points in DLQI total score in patients with baseline DLQI total score >5.

ITT, intent to treat; LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis.


  1. Thaçi D, Kimball A, Foley P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31(3):498-506.
  2. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507-517.
  3. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.